Yungjin Pharm Co Ltd (KO:003520) — Market Cap & Net Worth
Market Cap & Net Worth: Yungjin Pharm Co Ltd (003520)
Yungjin Pharm Co Ltd (KO:003520) has a market capitalization of $128.90 Million (₩190.21 Billion) as of September 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18314 globally and #812 in its home market, demonstrating a -6.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yungjin Pharm Co Ltd's stock price ₩1040.00 by its total outstanding shares 182892454 (182.89 Million). Also see how large is Yungjin Pharm Co Ltd's balance sheet for a full breakdown of the balance sheet.
Yungjin Pharm Co Ltd Market Cap History: 2015 to 2026
Yungjin Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $264.00 Million to $128.90 Million (-6.48% CAGR). Also see Yungjin Pharm Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Yungjin Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yungjin Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 003520 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Yungjin Pharm Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.20x
Yungjin Pharm Co Ltd's market cap is 0.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $264.00 Million | $170.20 Billion | $3.39 Billion | 0.00x | 0.08x |
| 2016 | $1.09 Billion | $193.13 Billion | $4.20 Billion | 0.01x | 0.26x |
| 2017 | $1.09 Billion | $195.01 Billion | $1.87 Billion | 0.01x | 0.58x |
| 2018 | $736.23 Million | $186.41 Billion | -$6.10 Billion | 0.00x | N/A |
| 2019 | $821.75 Million | $220.52 Billion | $5.03 Billion | 0.00x | 0.16x |
| 2020 | $996.51 Million | $208.46 Billion | -$133.12 Million | 0.00x | N/A |
| 2021 | $655.66 Million | $196.07 Billion | -$11.58 Billion | 0.00x | N/A |
| 2022 | $402.82 Million | $218.38 Billion | -$21.96 Billion | 0.00x | N/A |
| 2023 | $263.38 Million | $234.90 Billion | -$3.88 Billion | 0.00x | N/A |
| 2024 | $246.40 Million | $252.04 Billion | $1.23 Billion | 0.00x | 0.20x |
Competitor Companies of 003520 by Market Capitalization
Companies near Yungjin Pharm Co Ltd in the global market cap rankings as of September 17, 2026. Review Yungjin Pharm Co Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Yungjin Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Yungjin Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yungjin Pharm Co Ltd's market cap moved from $264.00 Million to $ 128.90 Million, with a yearly change of -6.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩128.90 Million | -48.00% |
| 2025 | ₩247.89 Million | +0.60% |
| 2024 | ₩246.40 Million | -6.45% |
| 2023 | ₩263.38 Million | -34.62% |
| 2022 | ₩402.82 Million | -38.56% |
| 2021 | ₩655.66 Million | -34.20% |
| 2020 | ₩996.51 Million | +21.27% |
| 2019 | ₩821.75 Million | +11.62% |
| 2018 | ₩736.23 Million | -32.35% |
| 2017 | ₩1.09 Billion | -0.45% |
| 2016 | ₩1.09 Billion | +314.08% |
| 2015 | ₩264.00 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Yungjin Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $128.90 Million USD |
| MoneyControl | $128.90 Million USD |
| MarketWatch | $128.90 Million USD |
| marketcap.company | $128.90 Million USD |
| Reuters | $128.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more